|

Sunitinib Malate Clinical Trials

1 actively recruiting trial across 1 location

No change since May 2026

Also known as: SU 011248, SU 11248, SU-011248, SU-11248, SU011248 +3 more

Pipeline

Phase 1: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Unresectable Pancreatic Neuroendocrine Tumor1
  • Stage IV Pancreatic Neuroendocrine Tumor AJCC v81
  • Stage III Pancreatic Neuroendocrine Tumor AJCC v81
  • Pancreatic Neoplasm1
  • Metastatic Pancreatic Neuroendocrine Tumor1

Duarte, California1 trial

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

City of Hope Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.